Format

Send to

Choose Destination
Clin Infect Dis. 2016 May 1;62(9):1119-25. doi: 10.1093/cid/ciw067. Epub 2016 Feb 7.

Prevention of Antibiotic-Nonsusceptible Invasive Pneumococcal Disease With the 13-Valent Pneumococcal Conjugate Vaccine.

Author information

1
Epidemic Intelligence Service Respiratory Diseases Branch, Centers for Disease Control and Prevention.
2
Minnesota Department of Health, St. Paul.
3
Vanderbilt University School of Medicine, Nashville, Tennessee.
4
University of California School of Public Health, Berkeley.
5
Colorado Department of Public Health & Environment, Denver.
6
Connecticut Department of Public Health, Hartford.
7
New York State Department of Health, Albany.
8
Oregon Public Health Division, Portland.
9
New Mexico Department of Health, Santa Fe.
10
John Hopkins University Bloomberg School of Public Health, Baltimore, Maryland.
11
Emory University School of Medicine Veterans Affairs Medical Center, Atlanta, Georgia.
12
Respiratory Diseases Branch, Centers for Disease Control and Prevention.

Abstract

BACKGROUND:

Antibiotic-nonsusceptible invasive pneumococcal disease (IPD) decreased substantially after the US introduction of the pediatric 7-valent pneumococcal conjugate vaccine (PCV7) in 2000. However, rates of antibiotic-nonsusceptible non-PCV7-type IPD increased during 2004-2009. In 2010, the 13-valent pneumococcal conjugate vaccine (PCV13) replaced PCV7. We assessed the impact of PCV13 on antibiotic-nonsusceptible IPD rates.

METHODS:

We defined IPD as pneumococcal isolation from a normally sterile site in a resident from 10 US surveillance sites. Antibiotic-nonsusceptible isolates were those intermediate or resistant to ≥1 antibiotic classes according to 2012 Clinical and Laboratory Standards Institute breakpoints. We examined rates of antibiotic nonsusceptibility and estimated cases prevented between observed cases of antibiotic-nonsusceptible IPD and cases that would have occurred if PCV13 had not been introduced.

RESULTS:

From 2009 to 2013, rates of antibiotic-nonsusceptible IPD caused by serotypes included in PCV13 but not in PCV7 decreased from 6.5 to 0.5 per 100 000 in children aged <5 years and from 4.4 to 1.4 per 100 000 in adults aged ≥65 years. During 2010-2013, we estimated that 1636 and 1327 cases of antibiotic-nonsusceptible IPD caused by serotypes included in PCV13 but not PCV7 were prevented among children aged <5 years (-97% difference) and among adults aged ≥65 years (-64% difference), respectively. Although we observed small increases in antibiotic-nonsusceptible IPD caused by non-PCV13 serotypes, no non-PCV13 serotype dominated among antibiotic-nonsusceptible strains.

CONCLUSIONS:

After PCV13 introduction, antibiotic-nonsusceptible IPD decreased in multiple age groups. Continued surveillance is needed to monitor trends of nonvaccine serotypes. Pneumococcal conjugate vaccines are important tools in the approach to combat antibiotic resistance.

KEYWORDS:

Streptococcus pneumoniae; antibiotic nonsusceptibility; pneumococcal conjugate vaccine; resistance

PMID:
26908787
DOI:
10.1093/cid/ciw067
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center